Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACLXNASDAQ:CRSPNASDAQ:FMTXNASDAQ:SWTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$64.95+0.4%$64.77$47.88▼$107.37$3.56B0.33554,529 shs305,269 shsCRSPCRISPR Therapeutics$38.67+3.4%$39.46$30.04▼$67.88$3.34B1.851.64 million shs2.08 million shsFMTXForma Therapeutics$20.01$20.00$4.95▼$20.68$957.54M-0.94847,595 shs1 shsSWTXSpringWorks Therapeutics$46.30+0.1%$45.49$28.21▼$62.00$3.47B0.791.87 million shs10.80 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx+0.25%+2.52%-4.78%+0.20%+26.61%CRSPCRISPR Therapeutics-1.27%-4.66%+1.11%-9.25%-31.79%FMTXForma Therapeutics0.00%0.00%0.00%0.00%0.00%SWTXSpringWorks Therapeutics+0.13%+14.17%-2.47%+26.62%-0.45%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACLXArcellx1.8405 of 5 stars3.60.00.00.03.12.50.0CRSPCRISPR Therapeutics2.7944 of 5 stars4.21.00.00.01.63.30.6FMTXForma TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASWTXSpringWorks Therapeutics1.9516 of 5 stars3.13.00.00.02.50.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACLXArcellx 3.14Buy$110.6770.39% UpsideCRSPCRISPR Therapeutics 2.48Hold$73.1189.05% UpsideFMTXForma Therapeutics 0.00N/AN/AN/ASWTXSpringWorks Therapeutics 2.13Hold$52.5713.55% UpsideCurrent Analyst Ratings BreakdownLatest FMTX, ACLX, SWTX, and CRSP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/30/2025SWTXSpringWorks TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$74.00 ➝ $47.004/29/2025SWTXSpringWorks TherapeuticsCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeHold4/29/2025SWTXSpringWorks TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$66.00 ➝ $47.004/28/2025SWTXSpringWorks TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$77.00 ➝ $47.004/28/2025SWTXSpringWorks TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/28/2025SWTXSpringWorks TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$63.00 ➝ $47.004/28/2025SWTXSpringWorks TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$81.00 ➝ $47.004/9/2025CRSPCRISPR TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$84.00 ➝ $84.002/21/2025SWTXSpringWorks TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$74.00 ➝ $74.002/20/2025SWTXSpringWorks TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$81.002/19/2025CRSPCRISPR TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACLXArcellx$107.94M33.14N/AN/A$9.97 per share6.51CRSPCRISPR Therapeutics$35M95.42N/AN/A$22.52 per share1.72FMTXForma Therapeutics$100.56M9.52N/AN/A$10.51 per share1.90SWTXSpringWorks Therapeutics$191.59M18.12N/AN/A$10.01 per share4.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACLXArcellx-$70.69M-$2.00N/AN/AN/A-25.94%-8.28%-5.21%5/8/2025 (Estimated)CRSPCRISPR Therapeutics-$366.25M-$4.37N/AN/AN/A-981.54%-18.46%-15.79%5/6/2025 (Estimated)FMTXForma Therapeutics-$172.96M-$4.00N/AN/AN/AN/A-39.68%-35.33%N/ASWTXSpringWorks Therapeutics-$325.10M-$3.48N/AN/AN/A-134.73%-46.74%-41.12%5/1/2025 (Estimated)Latest FMTX, ACLX, SWTX, and CRSP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025CRSPCRISPR Therapeutics-$1.26N/AN/AN/AN/AN/A5/8/2025Q1 2025ACLXArcellx-$0.84N/AN/AN/A$19.51 millionN/A5/1/2025Q1 2025SWTXSpringWorks Therapeutics-$0.79N/AN/AN/A$66.93 millionN/A2/27/2025Q4 2024ACLXArcellx-$0.63-$0.87-$0.24-$0.87$27.42 million$15.27 million2/20/2025Q4 2024SWTXSpringWorks Therapeutics-$0.66-$1.04-$0.38-$1.04$60.53 million$61.55 million2/11/2025Q4 2024CRSPCRISPR Therapeutics-$1.15-$0.44+$0.71-$0.44N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACLXArcellxN/AN/AN/AN/AN/ACRSPCRISPR TherapeuticsN/AN/AN/AN/AN/AFMTXForma TherapeuticsN/AN/AN/AN/AN/ASWTXSpringWorks TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACLXArcellxN/A4.294.29CRSPCRISPR TherapeuticsN/A22.0722.07FMTXForma TherapeuticsN/A12.7412.74SWTXSpringWorks TherapeuticsN/A6.166.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACLXArcellx96.03%CRSPCRISPR Therapeutics69.20%FMTXForma Therapeutics87.39%SWTXSpringWorks TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipACLXArcellx6.24%CRSPCRISPR Therapeutics4.10%FMTXForma Therapeutics5.79%SWTXSpringWorks Therapeutics7.83%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACLXArcellx8055.07 million50.70 millionOptionableCRSPCRISPR Therapeutics47386.36 million82.26 millionOptionableFMTXForma Therapeutics16647.85 million45.08 millionNot OptionableSWTXSpringWorks Therapeutics23074.98 million68.73 millionOptionableFMTX, ACLX, SWTX, and CRSP HeadlinesRecent News About These CompaniesPromising Value Stocks To Watch Now - April 28thApril 30 at 4:03 PM | marketbeat.comTop Mid Cap Stocks Worth Watching - April 28thApril 30 at 4:03 PM | marketbeat.comBest Pharmaceutical Stocks To Watch Now - April 28thApril 30 at 4:03 PM | marketbeat.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Receives Average Recommendation of "Moderate Buy" from BrokeragesApril 30 at 2:51 PM | marketbeat.comMedical Stocks To Add to Your Watchlist - April 28thApril 30 at 2:13 PM | marketbeat.comPromising Growth Stocks Worth Watching - April 28thApril 30 at 2:13 PM | marketbeat.comTop Biotech Stocks To Watch Today - April 28thApril 30 at 2:12 PM | marketbeat.comSpringWorks Therapeutics' (SWTX) "Equal Weight" Rating Reiterated at BarclaysApril 30 at 1:46 PM | marketbeat.comSpringWorks Therapeutics (NASDAQ:SWTX) Shares Gap Up - What's Next?April 30 at 12:17 PM | marketbeat.comSPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTXApril 30 at 11:57 AM | businesswire.comSpringWorks Therapeutics (NASDAQ:SWTX) Earns "Neutral" Rating from WedbushApril 30 at 10:39 AM | marketbeat.comGuggenheim Downgrades SpringWorks Therapeutics (SWTX)April 30 at 6:30 AM | msn.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Sold by Nebula Research & Development LLCApril 30 at 5:49 AM | marketbeat.comPrice T Rowe Associates Inc. MD Trims Stock Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)April 30 at 5:10 AM | marketbeat.comSpringWorks Therapeutics (SWTX) Projected to Post Earnings on ThursdayApril 30 at 3:35 AM | americanbankingnews.comSpringWorks Therapeutics' (SWTX) Neutral Rating Reiterated at WedbushApril 30 at 2:53 AM | americanbankingnews.comWall Street Analysts Believe SpringWorks Therapeutics (SWTX) Could Rally 42.29%: Here's is How to TradeApril 29 at 11:01 AM | zacks.comBarclays Downgrades SpringWorks Therapeutics (SWTX)April 29 at 7:59 AM | msn.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Purchased by Voya Investment Management LLCApril 29 at 5:47 AM | marketbeat.comBarclays Reiterates "Equal Weight" Rating for SpringWorks Therapeutics (NASDAQ:SWTX)April 29 at 3:29 AM | americanbankingnews.comHead to Head Review: Alpha Cognition (NASDAQ:ACOG) versus SpringWorks Therapeutics (NASDAQ:SWTX)April 29 at 1:37 AM | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFMTX, ACLX, SWTX, and CRSP Company DescriptionsArcellx NASDAQ:ACLX$64.95 +0.24 (+0.37%) As of 04:00 PM EasternArcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.CRISPR Therapeutics NASDAQ:CRSP$38.67 +1.27 (+3.40%) As of 04:00 PM EasternCRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Forma Therapeutics NASDAQ:FMTXForma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S.SpringWorks Therapeutics NASDAQ:SWTX$46.30 +0.06 (+0.13%) As of 04:00 PM EasternSpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
